Recent advances in cutaneous lymphomas

Journal of Dermatological Science

Volumn 48, Issue 3, 2007, Pages 157-167

  Dummer, Reinhard ^a   Asagoe, Kenji ^b   Cozzio, Antonio ^a   Burg, Günter ^a   Doebbeling, Udo ^a   Golling, Philippa ^a   Fujii, Kazuyasu ^a,b   Urosevic, Mirjana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cutaneous B cell lymphoma; Cutaneous T cell lymphoma; Mycosis fungoides; Pathogenesis; S zary syndrome

Indexed keywords

ALEMTUZUMAB; BEXAROTENE; CD4 ANTIGEN; CD56 ANTIGEN; DENILEUKIN DIFTITOX; GLUCOSE TRANSPORTER 1; ZANOLIMUMAB;

ASPERGILLOSIS; B CELL LYMPHOMA; BORRELIA BURGDORFERI; CANCER STAGING; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; FLU LIKE SYNDROME; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HYPOTENSION; LYMPHOCYTOMA; MYCOSIS FUNGOIDES; NAUSEA; ONCOGENE; PATHOGENESIS; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; VIRUS INFECTION; VOMITING; WORLD HEALTH ORGANIZATION;

HTLV-I INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 35649022643     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.09.001     Document Type: Review

References (84)

1. Vogelstein B.K.K. The multistep nature of cancer. Trends Genet 9 (1993) 138-141
2. Qin J.-Z.N.F., Häffner A., Dummer R., Burg G., and Döbbeling U. Cutaneous T cell lymphoma cells contain constitutive NFkB complexes. J Invest Derm 1997 (1997) 575
3. Qin J.-Z.K.J., Zhang C.-L., Dummer R., Burg G., and Döbbeling U. Constitutive and IL-7 and IL-15 stimulated DNA-binding of STAT and novel factors in cutaneous T cell lymphoma (CTCL) cells. J Invest Derm 117 (2001) 583-589
4. Qin J.-Z.Z.C.-L., Kamarashev J., Dummer R., Burg G., and Döbbeling U. IL-7 and IL-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T cell lymphoma (CTCL) cells. Blood 98 (2001) 2778-2783
5. Qin J.-Z.D.R., Burg G., and Döbbeling U. Constitutive and IL-7/Il-15 stimulated DNA-binding of Myc, Jun, and novel Myc-like proteins in cutaneous T cell Lymphoma cells. Blood 93 (1999) 260-267
6. Saharinen P.E.N., Sarvas K., Parker P., Alitalo K., and Silvennoinen O. The Bmx tyrosine kinase induces activation of the STAT signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood 90 (1997) 4341-4353
7. Döbbeling U.D.R., Laine E., Potoczna N., Qin J.-Z., and Burg G. IL-15 is an autocrine/paracrine viability factor for cutaneous T cell lymphoma cells. Blood 92 (1998) 252-258
8. Campbell G.S.Y.C., Jove R., and Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 272 (1997) 2591-2594
9. Li G.C.L., Wolfe J.T., Rook A.H., Felix A.C., Lessin S.R., and Salhany K.E. Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol 110 (1998) 767-770
10. Karenko L.H.S., Paivinen S., Karhu R., Syrja S., Kahkonen M., Nedoszytko B., et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 65 (2005) 8101-8110
11. Burg G., Kempf W., Cozzio A., Feit J., Willemze R., SJ E., et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 32 10 (2005) 647-674
12. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 10 (2005) 3768-3785
13. Cerroni L., Gatter K., and Kerl H. An illustrated guide to skin lymphoma (2004), Blackwell, Oxford
14. Goerdt S., Spieker T., and Wolffer L.U. Multiple cutaneous B-cell pseudolymphomas after allergen injections. J Am Acad Dermatol 34 6 (1996) 1072-1074
15. Crowson A.N., and Magro C.M. Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia. Arch Dermatol 131 8 (1995) 925-929
16. Peretz E., Grunwald M.H., Cagnano E., and Halevy S. Follicular B-cell pseudolymphoma. Australas J Dermatol 41 1 (2000) 48-49
17. Landa N.G., Zelickson B.D., Peters M.S., Muller S.A., and Pittelkow M.R. Lymphoma versus pseudolymphoma of the skin: gene rearrangement study of 21 cases with clinicopathologic correlation. J Am Acad Dermatol 29 6 (1993) 945-953
18. Bouloc A., Delfau-Larue M.H., Lenormand B., Meunier F., Wechsler J., Thomine E., et al. Polymerase chain reaction analysis of immunoglobulin gene rearrangement in cutaneous lymphoid hyperplasias. French Study Group for cutaneous lymphomas. Arch Dermatol 135 2 (1999) 168-172
19. Sangueza O.P., Yadav S., White Jr. C.R., and Braziel R.M. Evolution of B-cell lymphoma from pseudolymphoma. A multidisciplinary approach using histology, immunohistochemistry, and Southern blot analysis. Am J Dermatopathol 14 5 (1992) 408-413
20. Hammer E., Sangueza O., Suwanjindar P., White Jr. C.R., and Braziel R.M. Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasias. J Am Acad Dermatol 28 3 (1993) 426-433
21. Cerroni L., Zochling N., Putz B., and Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 24 8 (1997) 457-461
22. Goodlad J.R., Davidson M.M., Hollowood K., Batstone P., and Ho-Yen D.O. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 37 6 (2000) 501-508
23. Streubel B., Lamprecht A., Dierlamm J., Cerroni L., Stolte M., Ott G., et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101 6 (2003) 2335-2339
24. Streubel B., Simonitsch-Klupp I., Mullauer L., Lamprecht A., Huber D., Siebert R., et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18 10 (2004) 1722-1726
25. Streubel B., Vinatzer U., Lamprecht A., Raderer M., and Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19 4 (2005) 652-658
26. Schreuder M.I., Hoefnagel J.J., Jansen P.M., van Krieken J.H., Willemze R., and Hebeda K.M. FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma. J Pathol 205 3 (2005) 302-310
27. Grange F., Petrella T., Beylot-Barry M., Joly P., D'Incan M., Delaunay M., et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood 103 10 (2004) 3662-3668
28. Hoefnagel J.J., Dijkman R., Basso K., Jansen P.M., Hallermann C., Willemze R., et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105 9 (2005) 3671-3678
29. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., and Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100 17 (2003) 9991-9996
30. Dijkman R., Tensen C.P., Buettner M., Niedobitek G., Willemze R., and Vermeer M.H. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 107 12 (2006) 4926-4929
31. Petrella T., Bagot M., Willemze R., Beylot-Barry M., Vergier B., Delaunay M., et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 123 5 (2005) 662-675
32. Jacob M.C., Chaperot L., Mossuz P., Feuillard J., Valensi F., Leroux D., et al. CD4+CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 88 8 (2003) 941-955
33. Chan J.K.C., Jaffe E.S., and Ralfkiaer E. Blastic NK-cell lymphoma. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (World Health Organization classification of tumours) (2001), IARC Press, Lyon, France p. 214-215
34. Spits H., Lanier L.L., and Phillips J.H. Development of human T and natural killer cells. Blood 85 10 (1995) 2654-2670
35. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97 10 (2001) 3210-3217
36. Herling M., Teitell M.A., Shen R.R., Medeiros L.J., and Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+CD56+ blastic tumors of skin. Blood 101 12 (2003) 5007-5009
37. Petrella T., Meijer C.J., Dalac S., Willemze R., Maynadie M., Machet L., et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 122 2 (2004) 307-313
38. Feuillard J., Jacob M.C., Valensi F., Maynadie M., Gressin R., Chaperot L., et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99 5 (2002) 1556-1563
39. Garnache-Ottou F., Chaperot L., Biichle S., Ferrand C., Remy-Martin J.P., Deconinck E., et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 105 3 (2005) 1256-1264
40. Urosevic M., Conrad C., Kamarashev J., Asagoe K., Cozzio A., Burg G., et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol 36 9 (2005) 1020-1024
41. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194 12 (2001) 1823-1834
42. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., and Hart D.N. Characterization of human blood dendritic cell subsets. Blood 100 13 (2002) 4512-4520
43. Petrella T., Comeau M.R., Maynadie M., Couillault G., De Muret A., Maliszewski C.R., et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26 7 (2002) 852-862
44. Chaperot L., Perrot I., Jacob M.C., Blanchard D., Salaun V., Deneys V., et al. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 34 2 (2004) 418-426
45. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., and Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77 12 (1980) 7415-7419
46. Yoshida M., Miyoshi I., and Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79 6 (1982) 2031-2035
47. Manel N., Kim F.J., Kinet S., Taylor N., Sitbon M., and Battini J.L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115 4 (2003) 449-459
48. Blattner W.A. Human retroviruses: their role in cancer. Proc Assoc Am Physic 111 6 (1999) 563-572
49. Edlich R.F., Arnette J.A., and Williams F.M. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 18 1 (2000) 109-119
50. Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., and Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24 39 (2005) 6058-6068
51. Fujiyoshi T., Yashiki S., Fujiyama C., Kuwayama M., Miyashita H., Ohnishi H., et al. Ethnic segregation of HTLV-I and HTLV-II carriers among South American native Indians. Int J Cancer 63 4 (1995) 510-515
52. Parker C.E., Daenke S., Nightingale S., and Bangham C.R. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 188 2 (1992) 628-636
53. Arnulf B., Thorel M., Poirot Y., Tamouza R., Boulanger E., Jaccard A., et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 18 1 (2004) 126-132
54. Grassmann R., Aboud M., and Jeang K.T. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24 39 (2005) 5976-5985
55. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 19 (2001) 475-496
56. Karube K., Ohshima K., Tsuchiya T., Yamaguchi T., Kawano R., Suzumiya J., et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 126 1 (2004) 81-84
57. Roncador G., Garcia J.F., Garcia J.F., Maestre L., Lucas E., Menarguez J., et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 19 12 (2005) 2247-2253
58. Kohno T., Yamada Y., Akamatsu N., Kamihira S., Imaizumi Y., Tomonaga M., et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 96 8 (2005) 527-533
59. Matsubara Y., Hori T., Morita R., Sakaguchi S., and Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia 19 3 (2005) 482-483
60. Dosaka N., Tanaka T., Miyachi Y., Imamura S., and Kakizuka A. Examination of HTLV-I integration in the skin lesions of various types of adult T-cell leukemia (ATL): independence of cutaneous-type ATL confirmed by Southern blot analysis. J Invest Dermatol 96 2 (1991) 196-200
61. Takahashi K., Tanaka T., Fujita M., Horiguchi Y., Miyachi Y., and Imamura S. Cutaneous-type adult T-cell leukemia/lymphoma. A unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis. Arch Dermatol 124 3 (1988) 399-404
62. Yoshie O., Fujisawa R., Nakayama T., Harasawa H., Tago H., Izawa D., et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99 5 (2002) 1505-1511
63. Hasegawa H., Nomura T., Kohno M., Tateishi N., Suzuki Y., Maeda N., et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 95 1 (2000) 30-38
64. Harashima N., Kurihara K., Utsunomiya A., Tanosaki R., Hanabuchi S., Masuda M., et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 64 1 (2004) 391-399
65. Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 5 (2002) 1828-1834
66. Zhang Z., Zhang M., Goldman C.K., Ravetch J.V., and Waldmann T.A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63 19 (2003) 6453-6457
67. Willemze R., Kerl H., Sterry W., Berti E., Cerroni L., Chimenti S., et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90 1 (1997) 354-371
68. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. Tumours of hematopoietic and lymphoid tissues. World Health Organization classification of tumours (2001), IARC Press, Lyon, France
69. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
70. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Meth. Find Exp Clin Pharmacol 26 5 (2004) 357-391
71. Foss F.M. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann N Y Acad Sci 941 (2001) 166-176
72. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 2 (2001) 376-388
73. Gorgun G., and Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 100 4 (2002) 1399-1403
74. Foss F., Demierre M.F., and Divenuti G. A Phase I trial of Bexarotene and Denileukin Diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 107 12 (2005) 4926-4929
75. Flynn J.M., and Byrd J.C. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12 6 (2000) 574-581
76. Lundin J., Hagberg H., Repp R., Cavallin Stahl E., Freden S., Juliusson G., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 11 (2003) 4267-4272
77. Lundin J., Kennedy B., Dearden C., Dyer M.J., and Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 105 10 (2005) 4148-4149
78. Lenihan D.J., Alencar A.J., Yang D., Kurzrock R., Keating M.J., and Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104 3 (2004) 655-658
79. Hagberg H., Pettersson M., Bjerner T., and Enblad G. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 22 2 (2005) 191-194
80. Engert A., Burrows F., Jung W., Tazzari P.L., Stein H., Pfreundschuh M., et al. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res 50 1 (1990) 84-88
81. Klimka A., Barth S., Matthey B., Roovers R.C., Lemke H., Hansen H., et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 80 8 (1999) 1214-1222
82. Matthey B., Borchmann P., Schnell R., Tawadros S., Lange H., Huhn M., et al. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer 111 4 (2004) 568-574
83. Schnell R., Linnartz C., Katouzi A.A., Schon G., Bohlen H., Horn-Lohrens O., et al. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 63 2 (1995) 238-244
84. Zhang C., Richon V., Ni X., and Talpur R. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125 5 (2005) 1045-1052